Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 May 5;9(9):e015896.
doi: 10.1161/JAHA.120.015896. Epub 2020 May 2.

Pacemaker Implantation After Balloon- or Self-Expandable Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis

Arnaud Bisson  1 , Alexandre Bodin  1 , Julien Herbert  1   2 , Thibaut Lacour  1 , Christophe Saint Etienne  1 , Bertrand Pierre  1 , Nicolas Clementy  1 , Pierre Deharo  3   4   5 , Dominique Babuty  1 , Laurent Fauchier  1
Affiliations
Observational Study

Pacemaker Implantation After Balloon- or Self-Expandable Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis

Arnaud Bisson et al. J Am Heart Assoc. .

Erratum in

Abstract

Background The incidence of conduction abnormalities requiring permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) with early and later generation prostheses remains debated. Methods and Results Based on the administrative hospital-discharge database, we collected information for all patients treated with TAVR between 2010 and 2019 in France. We compared the incidence of PPI after TAVR according to the type and generation of valve implanted. A total of 49 201 patients with aortic stenosis treated with TAVR using the balloon-expandable (BE) Edwards SAPIEN valve (early Sapien XT and latest Sapien 3) or the self-expanding (SE) Medtronic CoreValve (early CoreValve and latest Evolut R) were found in the database. Mean (SD) follow-up was 1.2 (1.5 years) (median [interquartile range] 0.6 [0.1-2.0] years). PPI after the procedure was reported in 13 289 patients, among whom 11 010 (22.4%) had implantation during the first 30 days. In multivariable analysis, using early BE TAVR as reference, adjusted odds ratio (95% CI) for PPI during the first 30 days was 0.88 (0.81-0.95) for latest BE TAVR, 1.40 (1.27-1.55) for early SE TAVR, and 1.17 (1.07-1.27) for latest SE TAVR. Compared with early BE TAVR, the adjusted hazard ratio for PPI during the whole follow-up was 1.01 (0.95-1.08) for latest BE TAVR, 1.30 (1.21-1.40) for early SE TAVR, and 1.25 (1.18-1.34) for latest SE TAVR. Conclusions In patients with aortic stenosis treated with TAVR, our systematic analysis at a nationwide level found higher rates of PPI than previously reported. BE technology was independently associated with lower incidence rates of PPI both at the acute and chronic phases than SE technology. Recent generations of TAVR were not independently associated with different rates of PPI than early generations during the overall follow-up.

Keywords: aortic stenosis; pacemaker; transcatheter aortic valve implantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Incidence of permanent pacemaker implantation in patients treated with TAVR, according to type and generation of device.
BE indicates balloon‐expandable; Early BE, Edwards Sapien XT; Early SE, Medtronic Corevalve; Latest BE, Edwards Sapien 3; Latest SE, Medtronic Evolut; SE, self‐expandable; and TAVR, transcatheter aortic valve replacement.
See this image and copyright information in PMC

Comment in

References

    1. Nguyen V, Michel M, Eltchaninoff H, Gilard M, Dindorf C, Iung B, Mossialos E, Cribier A, Vahanian A, Chevreul K, et al. Implementation of transcatheter aortic valve replacement in France. J Am Coll Cardiol. 2018;71:1614–1627. - PubMed
    1. Deharo P, Bisson A, Herbert J, Lacour T, Saint Etienne C, Grammatico‐Guillon L, Porto A, Collart F, Bourguignon T, Cuisset T, et al. Impact of Sapien 3 balloon‐expandable versus evolut R self‐expandable transcatheter aortic valve implantation in patients with aortic stenosis: data from a nationwide analysis. Circulation. 2020;141:260–268. - PubMed
    1. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, et al. Transcatheter or surgical aortic‐valve replacement in intermediate‐risk patients. N Engl J Med. 2016;374:1609–1620. - PubMed
    1. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, et al.; PARTNER 3 Investigators . Transcatheter aortic‐valve replacement with a balloon‐expandable valve in low‐risk patients. N Engl J Med. 2019;380:1695–1705. - PubMed
    1. Reardon MJ, Adams DH, Kleiman NS, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Lee JS, Hermiller JB Jr, Chetcuti S, et al. 2‐year outcomes in patients undergoing surgical or self‐expanding transcatheter aortic valve replacement. J Am Coll Cardiol. 2015;66:113–121. - PubMed

Publication types

MeSH terms